Quantcast

Anavex appoints Peter Donhauser to its Board

Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointed Peter Donhauser, D.O. to its Board of Directors.

Dr. Donhauser has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases.

Dr. Donhauser said: “Anavex has reported promising 57-week data from its Phase 2a clinical trial in Alzheimer’s patients as well as positive preclinical data across a broad range of CNS diseases. I look forward to working with the team to advance the upcoming clinical programs in Rett syndrome, Parkinson’s and Alzheimer’s disease.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.